Real-World Prescribing of Renal and Cardiovascular Protective Drugs in Patients With Type 2 Diabetes and Chronic Kidney Disease: Analysis of Data From a Western Australian Quaternary Hospital.

Background: In patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), sodium-glucose cotransporter 2 (SGLT2) inhibitors, semaglutide (glucagon-like peptide-1 [GLP-1] agonist), and finerenone (non-steroidal mineralocorticoid receptor antagonist) improve renal and cardiovascular outcomes. We assessed real-world prescribing of these drugs in patients with T2D and CKD.

Method: The ReDiCare project retrospectively identified patients with T2D and CKD admitted to an Australian hospital between January 2020 and September 2024 using International Statistical Classification of Diseases and Related Health Problems 10th Revision Australian Modification codes.

The combined impact of chronic kidney disease and ulcer severity on incident cardiovascular events in patients with diabetes-related foot ulceration.

In patients with diabetes-related foot ulceration (DFU), ulcer severity and chronic kidney disease (CKD) portend worse outcomes. We evaluated the combined impact of a severe ulcer with CKD on major adverse cardiovascular events (MACE) in patients with DFU. Ulcer severity was defined using the SINBAD (site, ischaemia, neuropathy, bacterial infection, area, depth) classification, dividing into low (1-3) or high (4-6).

Achievement of low-density lipoprotein cholesterol goals in patients with diabetes-related foot ulceration.

Despite their elevated risk for cardiovascular complications, two-thirds of patients with diabetes-related foot ulceration in this contemporary real-world study were not achieving guideline-recommended goals for low-density lipoprotein cholesterol. Implementation research is needed to identify the barriers and facilitators to optimal lipid management in this high priority population.